. 2019 Nov 8;29(12):1507–1517. doi: 10.1089/lap.2019.0550

Table 2.

Design Characteristics of Studies Included in the Meta-Analysis

Study	Study ID	Treatment period	Number and location of sites	No. of patients	RFA trade name (manufacturer)	RFA delivery	Follow-up (months)
Bongers et al.¹⁵	FAST-EU; NCT01226290	—, 2013^a	7 Intercontinental	50	Sonata (Gynesonics)	TFA; US guidance	12 (6, 12)^b
Brölmann et al.¹⁶	FAST-EU; NCT01226290	—, 2013^a	7 Intercontinental	50	Sonata (Gynesonics)	TFA; US guidance	12 (6, 12)^b
Garza-Leal¹⁷	VITALITY	—	1 Mexico	17	Sonata (Gynesonics)	TFA; US guidance	64 (57, 73)^b
Braun et al.¹⁸	TRUST postmarket	2014, 2016	4 United States, Canada	40	Acessa (Acessa Health)	PL; US guidance	2 (0, 2)^b
Brucker et al.¹⁹	NCT01750008	2012, 2013	1 Germany	25	Acessa (Acessa Health)	PL; US guidance	21 (—, 24)^b
Hahn et al.²⁰
Krämer et al.²¹
Carrafiello et al.²²	—	2006, 2008	1 Italy	11	RF3000 (Boston Scientific)	PL; US guidance	9 (3, 12)^c
Cho et al.²³	—	2004, 2006	1 Korea	153	M-1004 (RF Medical System)	TV; US guidance	— (—, 18)^b
Cho et al.²⁴	—	2009, 2012	1 Korea	24	M-1004 (RF Medical System)	TV	— (—, 24)^b
Chudnoff et al.²⁵	Halt Phase III; NCT00874029	2009, 2011	9 United States, Latin America	135	Acessa (Acessa Health)	PL; US guidance	31 (—, 36)^b
Galen et al.²⁶
Guido et al.²⁷
Berman et al.²⁸
Chudnoff et al.²⁹	SONATA; NCT02228174	2015, 2016	22 United States, Mexico	147	Sonata (Gynesonics)	TFA; US guidance	22 (—, 24)^b
Miller and Osman³⁰	SONATA; NCT02228174	2015, 2016	22 United States, Mexico	147	Sonata (Gynesonics)	TFA; US guidance	22 (—, 24)^b
Galen et al.³¹	Halt Phase II	—, 2008^a	2 Latin America	69	Acessa (Acessa Health)	PL; US guidance	11 (3, 12)^b
Garza-Leal et al.³²
Robles et al.³³
Ghezzi et al.³⁴	—	2003, 2005	3 Italy	25	Model 1500X (AngioDynamics)	PL	24 (12, 36)^c
Bergamini et al.³⁵	—	2003, 2005	3 Italy	25	Model 1500X (AngioDynamics)	PL	24 (12, 36)^c
Iversen and Dueholm³⁶	—	2007, 2010	2 Norway, Denmark	66	Model 1500X (AngioDynamics)	PL; US guidance	59 (37, 74)^b
Iversen et al.³⁷	—	2007, 2010	2 Norway, Denmark	66	Model 1500X (AngioDynamics)	PL; US guidance	59 (37, 74)^b
Jiang et al.³⁸	—	2009, 2012	— China	46	BBT-RF-B (Ban Bian Tian)	TV; US guidance	— (—, 18)^b
Kim et al.³⁹	—	2004, 2008	— Korea	69	M-2004 (RF Medical System)	TV; US guidance	— (—, 12)^b
Lee et al.⁴⁰	—	2005, 2007	1 Korea	58	M-1004 (RF Medical System)	TV; US guidance	— (—, 18)^b
Marcos et al.⁴¹	—	2011, 2012	1 Spain	17	RF3000 (Boston Scientific)	PL; US guidance	6 (—, 6)^b
Meng et al.⁴²	—	2009, 2009	1 China	50	Cool-Tip (Medtronic)	PL; US guidance	<1^d
Rattray et al.⁴³	TRUST; NCT015663783	2012, 2017	≥2 Canada	23	Acessa (Acessa Health)	PL; US guidance	— (—, 3)^b
Rey et al.⁴⁴	—	2015, 2017	1 Spain	205	VIVA (STARmed)	TV; US guidance	— (—, 12)^b
Turtulici et al.⁴⁵	—	2017, 2018	1 Italy	19	VIVA (STARmed)	TV; US guidance	6 (6, 6)^b
Wu et al.⁴⁶	—	2010, 2012	1 China	51	DS98F-D (Huanghe)	TV; US guidance	11 (6, 12)^b

^{^a}

Estimated.

^{^b}

Mean (min, max).

^{^c}

Median (min, max).

^{^d}

In-hospital follow-up only.

PL, percutaneous laparoscopic; RFA, radiofrequency ablation; TFA, transcervical fibroid ablation; TV, transvaginal; US, ultrasound.